WO2019103436A3 - Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 - Google Patents

Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 Download PDF

Info

Publication number
WO2019103436A3
WO2019103436A3 PCT/KR2018/014294 KR2018014294W WO2019103436A3 WO 2019103436 A3 WO2019103436 A3 WO 2019103436A3 KR 2018014294 W KR2018014294 W KR 2018014294W WO 2019103436 A3 WO2019103436 A3 WO 2019103436A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
culturing
same
composition
cancer
Prior art date
Application number
PCT/KR2018/014294
Other languages
English (en)
French (fr)
Other versions
WO2019103436A2 (ko
WO2019103436A9 (ko
Inventor
안희정
최연호
임은진
문용화
김세화
Original Assignee
의료법인 성광의료재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 의료법인 성광의료재단 filed Critical 의료법인 성광의료재단
Priority to US16/645,215 priority Critical patent/US11746327B2/en
Priority to JP2020513912A priority patent/JP7119076B2/ja
Publication of WO2019103436A2 publication Critical patent/WO2019103436A2/ko
Publication of WO2019103436A3 publication Critical patent/WO2019103436A3/ko
Publication of WO2019103436A9 publication Critical patent/WO2019103436A9/ko
Priority to US18/353,182 priority patent/US11981924B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2327—Interleukin-27 (IL-27)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NK 세포 배양용 조성물 및 이를 이용하여 NK 세포를 배양하는 방법에 관한 것이다. 일 양상에 따르면, 말초혈액 단핵구에서 NK 세포를 배양함에 있어서, NK 세포를 IL-15, IL-18, 및 IL-27를 포함하는 NK 세포 배양용 조성물을 함유하는 배지에서 배양하여, 대량으로 증식시키고 NK 세포의 활성화를 촉진시킬 수 있다. 따라서, 이를 이용하는 경우, 암세포의 세포사멸 또는 살상능이 촉진될 수 있어, 암의 예방 또는 치료에 효과적인 입양 면역세포 치료제로 사용할 수 있다.
PCT/KR2018/014294 2017-11-24 2018-11-20 Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 WO2019103436A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/645,215 US11746327B2 (en) 2017-11-24 2018-11-20 Composition for culturing NK cells and method for culturing NK cells using same
JP2020513912A JP7119076B2 (ja) 2017-11-24 2018-11-20 Ｎｋ細胞培養用組成物、及びそれを利用してｎｋ細胞を培養する方法
US18/353,182 US11981924B2 (en) 2017-11-24 2023-07-17 Composition for culturing NK cells and method for culturing NK cells using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0158577 2017-11-24
KR1020170158577A KR102265437B1 (ko) 2017-11-24 2017-11-24 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/645,215 A-371-Of-International US11746327B2 (en) 2017-11-24 2018-11-20 Composition for culturing NK cells and method for culturing NK cells using same
US18/353,182 Continuation US11981924B2 (en) 2017-11-24 2023-07-17 Composition for culturing NK cells and method for culturing NK cells using same

Publications (3)

Publication Number Publication Date
WO2019103436A2 WO2019103436A2 (ko) 2019-05-31
WO2019103436A3 true WO2019103436A3 (ko) 2019-07-18
WO2019103436A9 WO2019103436A9 (ko) 2019-08-22

Family

ID=66630757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/014294 WO2019103436A2 (ko) 2017-11-24 2018-11-20 Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Country Status (4)

Country Link
US (2) US11746327B2 (ko)
JP (1) JP7119076B2 (ko)
KR (1) KR102265437B1 (ko)
WO (1) WO2019103436A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
WO2024014643A1 (ko) * 2022-07-11 2024-01-18 주식회사 노보셀바이오 세포 독성이 향상된 면역세포 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990042747A (ko) * 1997-11-28 1999-06-15 조생현 세포 배양용 무혈청 배지
KR20110132618A (ko) * 2009-03-26 2011-12-08 아바리스 아베 Ｎｋ 세포의 증식
KR20140123503A (ko) * 2011-12-22 2014-10-22 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물
KR20170000798A (ko) * 2015-06-24 2017-01-03 (주)차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
KR20170010865A (ko) * 2015-01-27 2017-02-01 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 함암제로서의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007129A (es) 2002-12-31 2005-08-26 Schering Corp Usos de la citocina de mamifero; reactivos relacionados.
EP2425847A1 (en) 2004-05-20 2012-03-07 ZymoGenetics, Inc. Methods of treating cancer using IL-21 and monoclonal antibody therapy
CA2830080C (en) * 2011-03-18 2021-10-26 Jan Spanholtz Generation of nk cells and nk-cell progenitors
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
JP6073417B2 (ja) 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990042747A (ko) * 1997-11-28 1999-06-15 조생현 세포 배양용 무혈청 배지
KR20110132618A (ko) * 2009-03-26 2011-12-08 아바리스 아베 Ｎｋ 세포의 증식
KR20140123503A (ko) * 2011-12-22 2014-10-22 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물
KR20170010865A (ko) * 2015-01-27 2017-02-01 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 함암제로서의 용도
KR20170000798A (ko) * 2015-06-24 2017-01-03 (주)차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물

Also Published As

Publication number Publication date
US11746327B2 (en) 2023-09-05
US11981924B2 (en) 2024-05-14
WO2019103436A2 (ko) 2019-05-31
US20230365932A1 (en) 2023-11-16
WO2019103436A9 (ko) 2019-08-22
KR102265437B1 (ko) 2021-06-15
US20210095249A1 (en) 2021-04-01
JP7119076B2 (ja) 2022-08-16
JP2021502796A (ja) 2021-02-04
KR20190060412A (ko) 2019-06-03

Similar Documents

Publication Publication Date Title
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
AU2012274478A8 (en) Method for amplifying NK cells
FI3578201T3 (fi) Menetelmiä ja koostumuksia luonnollisille tappajasoluille
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
NZ609201A (en) Means and methods for treating dlbcl
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
WO2012111997A3 (en) Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
MX2013008433A (es) Dispositivo medico que contiene una composicion en torta que comprende aripiprazol como ingrediente activo, y una composicion en torta que comprende aripirazol como ingrediente activo.
WO2019103436A3 (ko) Nk 세포 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
CA2749967A1 (en) Medicament for the treatment of pain and inflammation
MX2015006268A (es) Diferenciacion de las celulas de fibroblastos humanos.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2022003037A (es) Compuestos antibacterianos.
WO2020000035A8 (en) Modified t cells and uses thereof
JO3713B1 (ar) أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
PH12018501060A1 (en) Composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein
WO2008153150A1 (ja) Ｎｋ細胞を含む細胞集団の培養方法及び当該細胞集団の利用
ATE485832T1 (de) Glucoseisomerase zur behandlung von fructose- unverträglichkeit
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020513912

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18880968

Country of ref document: EP

Kind code of ref document: A2